bromocriptine has been researched along with vasoactive intestinal peptide in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (38.89) | 18.7374 |
| 1990's | 9 (50.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Makowska, A; Soszyński, P; Słowińska-Srzednicka, J; Zgliczyński, S; Zgliczyński, W | 1 |
| Bloom, SR; Ghatei, MA; Jones, PM; O'Halloran, DJ | 1 |
| Ichikawa, Y; Usuki, S | 1 |
| Gala, RR; Haisenleder, DJ; Lawson, DM; Moy, JA | 2 |
| Day, RN; Hinkle, PM | 1 |
| Jenkins, JS; Prysor-Jones, RA; Silverlight, JJ | 1 |
| Collu, R; Ducharme, JR; Eljarmak, D; Lafond, J; Marchisio, AM | 1 |
| Dimaline, R; Graham, K; Lightman, SL; McGarrick, G; Unwin, RJ | 1 |
| Blomquist, L; Goiny, M; Posloncec, B; Uvnäs-Moberg, K | 1 |
| Tamura, T; Watanobe, H | 1 |
| Carrillo, AJ; Liu, B; Signs, SA; Wolford, J | 1 |
| Sasaki, S; Takebe, K; Tamura, T; Watanobe, H | 1 |
| Alberici, A; Memo, M; Spano, P; Tinti, C; Valerio, A | 1 |
| Bende, M; Bergman, B; Sjögren, C | 1 |
| Balsa, JA; Cacicedo, L; Lara, JI; Lorenzo, MJ; Pazos, F; Sánchez-Franco, F | 1 |
| Bjøro, T; Gautvik, KM; Gordeladze, JO; Johansen, PW; Paulssen, RH | 1 |
| Balsa, JA; Gómez, O | 1 |
1 trial(s) available for bromocriptine and vasoactive intestinal peptide
| Article | Year |
|---|---|
Vasoactive intestinal polypeptide stimulation of prolactin release and renin activity in normal man and patients with hyperprolactinaemia: effects of pretreatment with bromocriptine and dexamethazone.
Topics: Adenoma; Adult; Bromocriptine; Dexamethasone; Female; Heart Rate; Hematocrit; Humans; Male; Pituitary Neoplasms; Prolactin; Renin; Vasoactive Intestinal Peptide | 1984 |
17 other study(ies) available for bromocriptine and vasoactive intestinal peptide
| Article | Year |
|---|---|
Increased plasma VIP concentration in patients with prolactinoma.
Topics: Adult; Analysis of Variance; Bromocriptine; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Vasoactive Intestinal Peptide | 1992 |
Rat anterior pituitary neuropeptides following chronic prolactin manipulation: a combined radioimmunoassay and mRNA study.
Topics: Animals; Blotting, Northern; Bromocriptine; Female; Galanin; Haloperidol; Hypothalamus; Neuropeptides; Peptides; Pituitary Gland, Anterior; Prolactin; Radioimmunoassay; Rats; Rats, Inbred Strains; RNA, Messenger; Substance P; Vasoactive Intestinal Peptide | 1991 |
Effects of hachimijiogan on dopamine, serotonin and vasoactive intestinal peptide in plasma and hypothalamus in sulpiride-induced hyperprolactinemic rats.
Topics: Animals; Bromocriptine; Dopamine; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Female; Hyperprolactinemia; Hypothalamus; Rats; Rats, Inbred Strains; Serotonin; Sulpiride; Vasoactive Intestinal Peptide | 1991 |
The effects of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in pseudopregnant rats.
Topics: Animals; Bromocriptine; Domperidone; Dopamine Antagonists; Female; Hysterectomy; Prolactin; Pseudopregnancy; Rats; Thyrotropin-Releasing Hormone; Time Factors; Vasoactive Intestinal Peptide | 1986 |
The effect of dopamine antagonists and/or VIP on TRH- or VIP-induced prolactin release in estrogen- and progesterone-treated ovariectomized rats.
Topics: Animals; Bromocriptine; Domperidone; Dopamine Antagonists; Drug Synergism; Estradiol; Female; Ovariectomy; Progesterone; Prolactin; Rats; Rats, Inbred Strains; Sulpiride; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide | 1988 |
Transient dopaminergic inhibition of prolactin release from hybrid cells derived by fusion of normal rat pituitary and GH4C1 tumor cells.
Topics: Animals; Bromocriptine; Cell Fusion; Cell Line; Cells, Cultured; Dopamine; Female; Growth Hormone; Hybrid Cells; Pituitary Gland; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred WF; Spiperone; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide | 1988 |
Hyperprolactinemia reduces vasoactive intestinal peptide in the anterior pituitary glands of rats.
Topics: Animals; Bromocriptine; Drug Implants; Estradiol; Female; Fluphenazine; Hyperprolactinemia; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Inbred Strains; Vasoactive Intestinal Peptide | 1987 |
Sodium ions: their role and mechanism of action in the control of prolactin release.
Topics: Animals; Bromocriptine; Cells, Cultured; Cobalt; Dopamine; Female; Haloperidol; Ouabain; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Inbred Strains; Sodium; Tetrodotoxin; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide; Veratridine | 1984 |
Increased levels of VIP (vasoactive intestinal polypeptide)-like immunoreactivity in peripheral venous blood of dogs following injections of apomorphine and bromocriptine. Do dopaminergic agents induce gastric relaxation and hypotension by a release of en
Topics: Animals; Apomorphine; Bromocriptine; Dogs; Gastrointestinal Hormones; Gastrointestinal Motility; Haloperidol; Hypotension; Muscle Relaxation; Receptors, Dopamine; Vasoactive Intestinal Peptide; Vomiting | 1982 |
Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly.
Topics: Acromegaly; Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Male; Middle Aged; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide | 1995 |
Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary.
Topics: 5-Hydroxytryptophan; alpha-Methyltyrosine; Animals; Blotting, Northern; Bromocriptine; Gene Expression Regulation; Haloperidol; Ketanserin; Male; Methiothepin; Methoxydimethyltryptamines; Methyltyrosines; Pituitary Gland, Anterior; Prolactin; Quipazine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Serotonin; Time Factors; Transcription, Genetic; Vasoactive Intestinal Peptide | 1994 |
Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
Topics: Acromegaly; Adult; Bromocriptine; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Male; Middle Aged; Prolactin; Sex Characteristics; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide | 1993 |
Antisense strategy unravels a dopamine receptor distinct from the D2 subtype, uncoupled with adenylyl cyclase, inhibiting prolactin release from rat pituitary cells.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Base Sequence; Bromocriptine; Cells, Cultured; Cyclic AMP; Female; Molecular Sequence Data; Oligonucleotides, Antisense; Pituitary Gland, Anterior; Polymerase Chain Reaction; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Spiperone; Vasoactive Intestinal Peptide | 1994 |
Nasal mucosal congestion after treatment with bromocriptine.
Topics: Adult; Airway Resistance; Bromocriptine; Estradiol; Female; Humans; Lactation; Nasal Cavity; Nasal Mucosa; Progesterone; Prolactin; Thyrotropin; Vasoactive Intestinal Peptide; Vasodilation | 1993 |
Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion.
Topics: Animals; Bromocriptine; Cells, Cultured; Dopamine; Gene Expression; Humans; Male; Pituitary Gland, Anterior; Prolactin; Rats; Receptors, Vasoactive Intestinal Peptide; RNA, Messenger; Triiodothyronine; Vasoactive Intestinal Peptide | 1996 |
Distinct guanine nucleotide binding protein alpha-subunit receptor coupling in GH cell lines: effects of bromocriptine and hormones on effector enzyme modulation.
Topics: Adenylyl Cyclases; Animals; Bromocriptine; Cell Line; Cell Membrane; Dopamine Agonists; Heterotrimeric GTP-Binding Proteins; Immune Sera; Phosphotransferases (Alcohol Group Acceptor); Pituitary Gland; Prolactin; Rats; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Thyrotropin-Releasing Hormone; Type C Phospholipases; Vasoactive Intestinal Peptide | 2001 |
Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression.
Topics: Animals; Blotting, Northern; Blotting, Western; Brain; Bromocriptine; Diethylstilbestrol; Dopamine; Dopamine Agonists; Estrogens, Non-Steroidal; Female; Hyperplasia; Pituitary Gland; Prolactin; Rats; Rats, Inbred F344; Receptors, Vasoactive Intestinal Peptide; RNA, Messenger; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasoactive Intestinal Peptide | 2004 |